AbCellera to report Phase 2 top-line data for menopause hot flash drug ABCL635 on Aug. 10

Reuters2026/08/07 20:30

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

AbCellera scheduled top-line Phase 2 results for ABCL635 in moderate-to-severe menopausal vasomotor symptoms for Aug. 10, 2026, before market open.
Data release will clarify whether the candidate showed a meaningful clinical benefit in easing symptoms, shaping next-step development and funding priorities.
An investor conference call is set for 4:30 a.m. PT to discuss the readout.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608071630BIZWIRE_USPR_____20260807_BW393777) on August 07, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

AbCellera to report Phase 2 top-line data for menopause hot flash drug ABCL635 on Aug. 10

You may also like

Crypto prices